Keeping the 100-year-old promise-making insulin access universal details the main barriers to accessing the lifesaving medicine, namely high prices, low availability of human insulin, a market dominated by just a few producers, and weak health systems.
century after it was discovered, insulin still remains out of reach for
many people living with diabetes, the World Health Organization (WHO)
said in a report published on Friday to commemorate the milestone
Diabetes is characterized by elevated levels of blood sugar which
over time, can cause serious damage to the heart, blood vessels, eyes,
kidneys and nerves. But sufferers use Insulin as the bedrock of diabetes treatment and for nine million people worldwide
living with type 1 diabetes, a chronic condition in which the pancreas
produces little or no insulin, having access to the drug turns the disease
into a manageable condition.
Now in its report, titled keeping the 100-year-old promise-making insulin access universal,
the World Health details
prices, low availability of human insulin, a market dominated by just a
few producers, and weak health systems as the main barriers to access the lifesaving medicine.
“The scientists who discovered insulin 100 years ago refused
to profit from their discovery and sold the patent for just one dollar,”
said Tedros Adhanom Ghebreyesus, Director-General of the UN agency. “Unfortunately, he adds, that gesture of solidarity has been overtaken
by a multi-billion-dollar business that has created vast access gaps.”
WHO said that for more than 60 million people living with type 2 diabetes,
a condition which occurs when the body becomes resistant to insulin or doesn't make
enough of it, the drug is essential to reduce the risk of kidney failure, blindness
and amputation. However, one in two people who need the medicine do not
While diabetes is increasing in low and middle-income countries,
their consumption of insulin has not kept up with the growing disease
burden. WHO explained that global markets have shifted from human insulin,
which can be produced at relatively low cost, to pricier synthetic
insulins, which can be up to three times more expensive.
The UN agency called for improved affordability by regulating prices
and mark-ups through pooled procurement and greater price transparency
and promoting local manufacturing capacity in under-served regions.
The report outlines measures to improve access to insulin and related products. Actions include boosting human insulin production and supply and
diversifying manufacturing of biosimilar products to create competition
and reduce prices.
At the same time, research and development (R&D) should be
centred on the needs of low and middle-income countries, while increased
access to insulin should be accompanied by prompt diagnosis along with
access to affordable devices for injecting the medicine and monitoring